Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of TAS-117 in Advanced Solid Tumors with Germline PTEN Inactivating Mutations
2020-004770-22Phase 2Completed
- Sponsor
- Taiho Oncology
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pifusertib in Nonhematologic neoplasms, sponsored by Taiho Oncology. Primary endpoints: Maximum tolerated dose (MTD), Recommended Phase 2 dose (RP2D) and 1 more. Started Jan 2021; status: completed.
02
Drugs
pifusertib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2020-004770-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004770-22.